MBX Biosciences (MBX) announced the publication of a peer-reviewed article highlighting results from the Phase 1 study of MBX 2109, the ...

Peer-reviewed publication features positive results from multiple ascending dose (MAD) portion of Phase 1 MBX 2109 study in ...

MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the ...

IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) has been assigned an average rating of “Hold” from the eight analysts that are presently covering the firm, MarketBeat.com reports.

The likes of BioAge Labs Inc and MBX Biosciences Inc will seek to buck that trend with industry bankers and lawyers saying the market’s reaction to the next batch will signal whether others can ...

MBX Biosciences and Septerna Therapeutics have stirred the biotech industry and the hypoparathyroidism treatment space alike. U.S.-based MBX’s $187.7 million offering will fund its lead candidate MBX ...

CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...

CARMEL, Ind. – MBX Biosciences, Inc. (NASDAQ:MBX) has announced the completion of its Phase 1 trial for MBX 1416, a potential treatment for post-bariatric hypoglycemia (PBH), a condition with no ...

CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...